Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates

Journal of Dental Research

Volumn 86, Issue 11, 2007, Pages 1022-1033

  Kimmel, D B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bone metastasis; Bone remodeling; Farnesyl pyrophosphase synthase; Half life; Osteoclast; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; GERANYLTRANSFERASE; NITROGEN;

ARTICLE; BONE; BONE REMODELING; BONE TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HALF LIFE TIME; HUMAN; HYPERCALCEMIA; METABOLISM; METASTASIS; MULTIPLE MYELOMA; OSTEOCLAST; POSTMENOPAUSE OSTEOPOROSIS;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; DIPHOSPHONATES; FEMALE; GERANYLTRANSTRANSFERASE; HALF-LIFE; HUMANS; HYPERCALCEMIA; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; NITROGEN; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 36549010158     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910708601102     Document Type: Article

References (141)

1. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. (1987). The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331.
2. Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Monkkonen J, et al. (2002). Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40-47.
3. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, et al. (2001). Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434-3437.
4. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, et al. (1992). Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663.
5. Arikoski P, Silverwood B, Tillmann V, Bishop NJ (2004). Intravenous Pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy x-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 34:539-546.
6. Barrett J, Worth E, Bauss F, Epstein S (2004). Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharm 44:951-965.
7. Bauss F, Russell RGG (2004). Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osleoporos Int 15:423-433.
8. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ (1999). Farnesol and geranylgeraniol prevent activation of caspases by aminobisphophonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56:131-140.
9. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. (1998). Long-term Pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16:593-602.
10. Berenson JR, Ravera C, Ma P (2002). Population pharmacokinetics of zoledronate (abstract). Proc Am Soc Clin Oncol 23:209.
11. Berkhout TA, Simon HM, Patel DD, Bentzen C, Niesor E, Jackson B, et al. (1996). The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3methylglutaryl- coenzyme A reductase. J Biol Chem 271:14376-14382.
12. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535-1541.
13. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Lewis S, Quandt SA, et al. (2006). Effects of continuing or stopping alendronate after five years of treatment. J Am Med Assoc 296:2927-2938.
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (2007). Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
15. Body JJ, Diel LJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 19:1399-1405.
16. Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, et al. (1997). Dose response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265-274.
17. Briot K, Tremollieres F, Thomas T, Roux C, Comité Scientifique du GRIO (2007). How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 74:24-31.
18. Brown JE, Neville-Webbe H, Coleman RE (2004). The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11:207-224.
19. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995). Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9-16.
20. Chang JT, Green L, Beitz J (2004). Renal failure with the use of zoledronic acid. N Engl J Med 349:1676-1679.
21. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, et al. (2007). Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Min Res 22:1502-1509
22. Chen T, Berenson JR, Vescio R, Swift R, Gilchick A, Goodin S, et al. (2002). Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharm 42:1228-1236.
23. Ciosek CP Jr, Magnin DR, Harrity TW, Logan JVH, Dickson JK Jr, Gordon EM, et al. (1993). Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally-active cholesterol-lowering agents in vivo. J Biol Chem 268:24832-24837.
24. Clezardin P, Ebetino FH, Fournier PGJ (2005). Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Can fira 65:4971-4974.
25. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CF, Rogers MJ (2005). Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37:349-358.
26. Cremers S, Sparidans R, den Hartigh J, Hamdy N, Vermeij P, Papapoulos SE (2002). A pharmacokinetic and pharmacodynamic model of intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 57:883-890.
27. Cremers SC, Eekhoff ME, Den Hartigh J, Hamady NA, Vermeij P, Papapoulos SE (2003). Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 18:868-875.
28. Cremers SCLM, Pillai G, Papapoulos SE (2005). Pharmaco-kinetics/ pharmacodynamics of bisphosphonates. Clin Pharmacokinet 44:551-570.
29. Cummings SR, Black DM, Rubin SM (1989). Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445-2448.
30. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. J Am Med Assoc 280:2077-2082.
31. De Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, et al. (2007). A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222-1230.
32. Diel IJ, Body JJ, Lichinitser MR. Kreuser ED, Dornoff W, Gorbunova VA, et al. (2004). Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Can 40:1704-1712.
33. Drug Topics (issues of 19-Feb-2007 and 5-Mar-2007). New York: Advanstar Communications, http://drugtopics.com
34. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. (2001). Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
35. Dunn CJ, Goa KL (2001). Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 61:685-712.
36. Epstein S (2006). Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 28:151-173.
37. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. (1999). Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138.
38. Fleisch H (1991). Bisphosphonates - pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs 42:919-944.
39. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR (1978). The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. JNucl Med 19:270-275.
40. Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB (2007). Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 40:1172-1177.
41. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. (2002). Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544.
42. Frost HM (1969). Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 3:211-237.
43. Fujita H, Utsumi T, Muranaka S, Ogino T, Yano H, Akiyama J, et al. (2005). Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol 69:1773-1784.
44. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000). Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526-1536.
45. Giguere Y, Rousseau F (2000). The genetics of osteoporosis: complexities and difficulties. Clin Genet 57:161-169.
46. Giversen IM (2007). Time trends of mortality after first hip fractures. Osteoporos Int 18:721-732.
47. Gold DT, Safi W, Trinh H (2006). Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383-2391.
48. Graham DY (2002). What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 47:1665-1678.
49. Hamma-Kourbali Y, DiBenedetto M, Ledoux D, Oudar O, Leroux Y, Lecouvey M, et al. (2003). A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun 310:816-823.
50. Hasmim M, Bieler G, Ruegg C (2007). Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Throm Haemo 5:166-173.
51. Heaney RP, Recker RR, Saville PD (1978). Menopausal changes in calcium balance performance. J Lab Clin Med 92:953-963.
52. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. (2007). Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 22:142-148.
53. Hui SL, Slemenda CW, Johnston CC Jr (1989). Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 111:355-361.
54. Jung A, Bisaz S, Fleisch H (1973). The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269-280.
55. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, et al. (1997). Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner fiei 12:1700-1707.
56. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA (1987). Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 317:1169-1174.
57. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, et al. (2004). Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:999-1005.
58. Kristensen B, Ejlertsen B, Mouridsen HT, Loft H (1998). Survival in breast cancer patients after the first episode of hypercalcemia. J Intern Med 244:: 189-198.
59. Langston AL, Ralston SH (2004). Management of Paget's disease of bone. Rheumatology (Oxford) 43:955-959.
60. Lasseter KC, Porras AG, Denker A, Santhanagopal A, Daifotis A (2005). Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig 26:107-114.
61. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA (2006). Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38:628-636.
62. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, et al. (1995). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
63. Lin JH (1996). Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85.
64. Lin JH, Chen IW, Duggan DE (1992). Effect of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20:473-478.
65. Lindsay R, Hart DM, Sweeney A, Courts JRT, Clarke A (1977). Osteopenia and osteoporosis: endogenous estrogen and bone loss following oophorectomy. Calcif Tissue Res 22:213-216.
66. Lo JC, Pressman AR, Omar MA, Ettinger B (2006). Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922-928.
67. Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ (1998). Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 7:581-589.
68. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al. (1994). Pamidronate-an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320-322.
69. Magnin DR, Biller SA, Dickson JK Jr, Logan JVH, Lawrence RM, Chen Y, et al. (1995). 1,1-bisphosphonate squalene synthase inhibitors: interplay between isoprenoid subunit and the diphosphate surrogate. J Med Chem 38:2596-2605.
70. Masarachia P, Weinreb M, Balena R, Rodan GA (1996). Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19:281-290.
71. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000). Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620.
72. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001). Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531.
73. McClung MR, Geusens P, Miller PD, Zippel H, Benson WG, Rout C, et al. (2001). Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340.
74. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2005). Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462-468.
75. Mishra A, Wong L, Jonklaas J (2001). Prolonged symptomatic hypocalcemia with Pamidronate administration and subclinical hypoparathyroidism. Endocrine 14:159-164.
76. Mitchell DY, Barr WH, Eusebio RA, Pallone-Stevens KA, Duke FP, Russell DA, et al. (2001). Risedronate pharmacokinetics and intrand inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 18:166-170.
77. Mori S, Harruff R, Ambrosius W, Burr DB (1997). Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 21:521-526.
78. Mulari M, Vaaraniemi J, Vaananen HK (2003). Intracellular membrane trafficking in bone resorbing osteoclasts. Microscopy Res and Technique 61:496-503.
79. Orwoll ES, Klein RF (1995). Osteoporosis in men. Endocr Rev 16:87-116.
80. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM (1981). Menopausal estrogen therapy and hip fractures. Ann Intern Med 95:28-31.
81. Papapoulos SE (2006). Bisphosphonate actions: physical chemistry revisited. Bone 38:613-616.
82. Parfitt AM (1976). The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part I of IV Parts. Mechanisms of calcium transfer between blood and bone and their cellular basis: morphological and kinetic approaches to bone turnover. Metabolism 25:809-844.
83. Parfitt AM, Mathews CHE, Villanueva AR, Rao DS, Rogers M, Kleerekoper M, et al. (1983). Microstructural and cellular basis of age-related bone loss and osteoporosis. In: Clinical disorders of bone and mineral metabolism. Frame B, Potts JT, editors. Amsterdam: Excerpta Medica, Elsevier, pp. 328-330.
84. Pavios NJ, Xu J, Riedel D, Yeoh JSG, Teitelbaum SL, Papadimitriou JM, et al. (2005). Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol 25:5253-5269.
85. Peter R, Mishra V, Fraser WD (2004). Severe hypocalcemia after being given intravenous bisphosphonate. BMJ 328:335-336.
86. Pfister T, Atzpodien E, Bohrmann B, Bauss F (2005). Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 97:374-381.
87. Piscitelli P, Iolascon G, Gimigliano F, Muratore M, Camboa P, Borgia O, et al. (2007). Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population. Osteoporos Int 18:211-219.
88. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999). Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374.
89. Podenphant J, Gotfredsen A, Nilas L, Norgaard H, Braendstrup O (1986). Iliac crest biopsy: representativity for the amount of mineralized bone. Bone 7:427-430.
90. Poole KES, Compston JE (2006). Osteoporosis and its management. Br Med .7333:1251-1256.
91. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, et al. (1994). The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366-371.
92. Rauch F, Plotkin H, Zeitlin L, Glorieux FH (2003). Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous Pamidronate therapy. J Bone Miner Res 18:610-614.
93. Recker RR, Deng HW (2002). Role of genetics in osteoporosis. Endocrine 17:55-66.
94. Recker RR, Heaney RP, Saville PD (1978). Menopausal changes in bone remodeling. J Lab Clin Med 92:964-970.
95. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S (1988). Static and tetracycline-based bone histomorphometric data from 34 normal post-menopausal females. J Bone Miner Res 3:133-144.
96. Recker R, Lappe J, Davies KM, Heaney RP (2004). Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19:1628-1633.
97. Reginster JY (2005). Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des 11:3711-3728.
98. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. (2000). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
99. Ribatti D, Nico B, Mangieri D, Maruotti N, Longo V, Vacca A, et al. (2007). Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol 26:1094-1098.
100. Ringe JD, Farahmand P (2007). Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clin Rheumatol 26:474-484.
101. Rizzoli R, Greenspan SL, Bone HG III, Schnitzer TJ, Watts NB, Adami S, et al. (2002). Two year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Min Res 17:1988-1996.
102. Robbins JA, Biggs ML, Cauley J (2006). Adjusted mortality after hip fracture: from the cardiovascular health study. J Am Geriatr Soc 54:1885-1891.
103. Rodan GA, Fleisch HA (1996). Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2696.
104. Rogers MJ, Watts DJ, Russell RGG (1997). Overview of bisphosphonates. Cancer 80:1682-1660.
105. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, et al. (2005). Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double blind study. J Bone Min Res 20: 141-151.
106. Russell RGG (2006). Bisphosphonates: from bench to bedside. Ann NY Acad Sci 1068:367-401.
107. Russell RGG (2007). Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):S150-S162.
108. Saad F (2007). Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma. European Urology (Suppl 6):683-688.
109. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468.
110. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882.
111. Sambrook P (2003). Once weekly alendronate. Drugs of Today 39:339-346.
112. Sanders JM, Ortiz-Gomez A, Mao J, Meints GA, Van Brussel EM, Burzynska A, et al. (2003). 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem 46:5171-5182.
113. Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, Raker AM, et al. (2004). Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 47:375-384.
114. Sanders JM, Song Y, Chan JMW, Zhang Y, Jennings S, Kosztowski T, et al. (2005). Pyridinium-1-y 1 bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem 48:2957-2963.
115. Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G (2006a). Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 6:1333-1348.
116. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, et al. (2006b). Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 15:1351-1357.
117. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. (2007). Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482-4486.
118. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. (1991). Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
119. Schaffler MB, Choi K, Milgrom C (1995). Aging and matrix microdamage accumulation in human compact bone. Bone 17:521-525.
120. Schenk R, Eggli P, Fleisch H, Rosini S (1986). Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349.
121. Scoppola A, Galiano P (1998). The mevalonate pathway and renal disease: experimental and clinical implications. Int J Artif Organs 21:245-246.
122. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ (1998). The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294-5297.
123. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002). Patient preference for once weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized open-label, crossover study. Clin Ther 24:1871-1886.
124. Stark WW Jr, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, et al. (1998). Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscles. Am J Physiol 275:L55-L63.
125. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F (1989). A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10:313-320.
126. Stepensky D, Kleinberg L, Hoffman A (2003). Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 42:863-881.
127. Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, et al. (2001). Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-inducd gastrointestinal toxicity. Bone 29:336-343.
128. Szabo CM, Martin MB, Oldfield E (2002). An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. J Med Chem 45:2804-2903.
129. Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, et al. (1997). An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386-392.
130. Thompson K, Rogers MJ (2004). Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278-288.
131. van Beek E, Lowik CWGM, Ebetino FH, Papapoulos SE (1998). Binding and anti-resorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 23:438-442.
132. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos SE (1999a). Farnesyl pyrophosphate synthase is the molecular target of nitrogencontaining bisphosphonates. Biochem Biophys Res Commun 264:108-111.
133. Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999b). Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491-494.
134. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, LaCesa A, et al. (2005). Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144-151.
135. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR (1980). Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198.
136. Wenzel TE, Schaffler MB, Fyhrie DP (1996). In vivo trabecular microcracks in human vertebral bone. Bone 19:89-95.
137. Whyte MP (2006). Paget's disease of bone. N Engl J Med 355:593-600.
138. Woo JT, Nakagawa H, Krecic AM, Nagai K, Hamilton AD, Sebti SM, et al. (2005). Inhibitory effects of mevastatin and a geranylgeranyl transferase-I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NFKB ligand (RANKL) or tumor necrosis factor-a (TNF-a). Biochem Pharmacol 69:87-95.
139. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. (2002). Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061.
140. Zager RA, Shaw VO, Shaw HV, Zager PG, Johnson ACM, Hanson S (2002). The mevalonate pathway during acute tubular injury: selected determinants and consequences. Am J Pathol 161:681-692.
141. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, et al. (1995). The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 108:2285-2292.